ABCELLERA BIOLOGICS (8QQ) - Total Liabilities
Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) has total liabilities worth €390.05 Million EUR (≈ $456.00 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of ABCELLERA BIOLOGICS to track the company's year-over-year net asset growth rate.
ABCELLERA BIOLOGICS - Total Liabilities Trend (2021–2025)
This chart illustrates how ABCELLERA BIOLOGICS's total liabilities have evolved over time, based on quarterly financial data. See ABCELLERA BIOLOGICS (8QQ) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
ABCELLERA BIOLOGICS Competitors by Total Liabilities
The table below lists competitors of ABCELLERA BIOLOGICS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bitfarms Ltd.
NASDAQ:KEEL
|
USA | $735.97 Million |
|
Cairn Homes PLC
IR:C5H
|
Ireland | €522.49 Million |
|
Alphatec Holdings Inc
NASDAQ:ATEC
|
USA | $781.22 Million |
|
Beijing Lier High Temperature Materials Co Ltd
SHE:002392
|
China | CN¥4.38 Billion |
|
Cosmo Pharmaceuticals N.V
F:C43
|
Germany | €123.46 Million |
|
Xiamen King Long Motor Group Co Ltd
SHG:600686
|
China | CN¥23.55 Billion |
|
Gudeng Precision Industrial Co Ltd
TWO:3680
|
Taiwan | NT$11.21 Billion |
|
Rizhao Port Co Ltd
SHG:600017
|
China | CN¥23.58 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ABCELLERA BIOLOGICS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABCELLERA BIOLOGICS (8QQ) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABCELLERA BIOLOGICS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABCELLERA BIOLOGICS (2021–2025)
The table below shows the annual total liabilities of ABCELLERA BIOLOGICS from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €390.05 Million ≈ $456.00 Million |
+28.11% |
| 2024-12-31 | €304.47 Million ≈ $355.96 Million |
-9.32% |
| 2023-12-31 | €335.78 Million ≈ $392.56 Million |
+9.15% |
| 2022-12-31 | €307.63 Million ≈ $359.65 Million |
+5.05% |
| 2021-12-31 | €292.84 Million ≈ $342.36 Million |
-- |
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more